2023
IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression
Tang H, Panse G, Braddock D, Perincheri S, Xu M, McNiff J. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. Journal Of Cutaneous Pathology 2023, 50: 595-600. PMID: 37082914, DOI: 10.1111/cup.14439.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmPlasmacytoid dendritic cell neoplasmDendritic cell neoplasmPunch biopsy specimenBiopsy specimenCell neoplasmsCase of BPDCNUseful markerTumor cellsTCL-1 expressionAtypical mononuclear cellsBone marrow involvementDiffuse dermal infiltrateDendritic cell lineagePotential diagnostic pitfallRegulatory factor 8TCL-1BPDCN casesCD123 expressionMarrow involvementDermal infiltrateCutaneous nodulesMyelodysplastic syndromeSkin nodulesMononuclear cells
2022
Liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms.
Mata D, Xu M, Shanmugam V, Tukachinsky H, Schrock A, Ross J, Williams E, Montesion M, Decker B, Vergilio J, Oxnard G, Benhamida J. Liquid biopsy (LB)-based comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) for the evaluation of patients with myeloid neoplasms. Journal Of Clinical Oncology 2022, 40: e19064-e19064. DOI: 10.1200/jco.2022.40.16_suppl.e19064.Peer-Reviewed Original ResearchComprehensive genomic profilingAcute myeloid leukemiaMyelodysplastic syndromeHistiocytic neoplasmsMyeloproliferative neoplasmsMyeloid neoplasiaAML casesMinimal residual disease testingPathogenic alterationsHybrid-capture next-generation sequencingSolid tumor diagnosisEvaluation of patientsRoutine clinical careRelevant genomic alterationsMonitoring of patientsUnique patient samplesRetrospective studyMyeloid leukemiaMyeloid neoplasmsClinical carePatientsKRAS G12AInsufficient tumorDisease testingPathway alterations